UPDATE 1-Cumberland recalls 6 lots of liver drug
* Says recall due to presence of fine particles in vials
* Shares down 2 pct after-market
Dec 30 (Reuters) - Cumberland Pharmaceuticals Inc (CPIX.O) started a voluntary recall of 6 lots of its injectable liver drug due to presence of fine particles in some vials.
The Nashville, Tennessee-based Cumberland said the source of the particulate matter was from the glass vial produced by a former supplier.
Cumberland said the recall is a precautionary measure and is not based on any adverse events.
"We are recalling certain lots manufactured by a previous packaging supplier as a precautionary measure, and believe the risk of any serious adverse medical events to be remote," Chief Executive A.J. Kazimi said.
The drug Acetadote is currently approved to treat liver failure caused by an overdose of acetaminophen, a common ingredient in painkillers.
The company's shares, which have fallen 8 percent since the U.S. regulator declined to approve the drug for an additional indication last week, were down 2 percent at $5.95 in after-market trade. They closed at $6.09 on Thursday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Roshni Menon)
- U.S. war veteran released by North Korea returns home |
- South Korea to make announcement on air zone; expansion is anticipated |
- Pro-Europe protesters gather for rally in Kiev
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- Obama defends interim Iran deal, seeks to assure Israel